Jeffrey Reid, MD
Pulmonary Disease · Carrollton, GANPI 1639104748
Payments from drug & device makers
Across 165 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$914
- Insmed, Inc.$238
- Novo Nordisk$171
- Boehringer Ingelheim$163
- Sanofi$160
- Pfizer$124
- plus $894 from 20 others
What the payments were for
- Food & beverage$2,56796%
- Education$974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $914 |
| Insmed, Inc. | 11 | $238 |
| Novo Nordisk | 11 | $171 |
| Boehringer Ingelheim | 8 | $163 |
| Sanofi | 8 | $160 |
| Pfizer | 7 | $124 |
| AstraZeneca | 8 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Johnson & Johnson | 7 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Amgen | 5 | $77 |
| Inspire Medical Systems, Inc. | 2 | $76 |
| Lilly USA, LLC | 3 | $43 |
| Philips North America LLC | 2 | $42 |
| AbbVie | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Harmony Biosciences LLC | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Resmed Corp | 1 | $15 |
How this compares
$2,664 in reported general payments places this provider in the 35th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 902 | $802,497 |
| OfevNintedanib Esylate | 37 | $420,860 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 269 | $161,767 |
| Spiriva RespimatTiotropium Bromide | 164 | $104,984 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 119 | $63,499 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $62,407 |
| SymbicortBudesonide/Formoterol Fumarate | 212 | $56,067 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $42,432 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,179 | $42,002 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 58 | $34,808 |
| EliquisApixaban | 42 | $28,907 |
| Spiriva HandihalerTiotropium Bromide | 26 | $19,721 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $15,653 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 114 | $15,624 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 21 | $10,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $914 | $944,0561,170 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $163 | $722,419528 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $114 | $109,416279 claims |
| PfizerEliquis | $124 | $28,90742 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $32 | $7,62327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Carrollton
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.